MX359555B - Anticuerpos para tau. - Google Patents
Anticuerpos para tau.Info
- Publication number
- MX359555B MX359555B MX2014016024A MX2014016024A MX359555B MX 359555 B MX359555 B MX 359555B MX 2014016024 A MX2014016024 A MX 2014016024A MX 2014016024 A MX2014016024 A MX 2014016024A MX 359555 B MX359555 B MX 359555B
- Authority
- MX
- Mexico
- Prior art keywords
- tau
- antibodies
- methods
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Abstract
La presente invención se refiere a anticuerpos para tau y a métodos de uso de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261667515P | 2012-07-03 | 2012-07-03 | |
US201261694989P | 2012-08-30 | 2012-08-30 | |
PCT/US2013/049333 WO2014008404A1 (en) | 2012-07-03 | 2013-07-03 | Antibodies to tau |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014016024A MX2014016024A (es) | 2015-04-13 |
MX359555B true MX359555B (es) | 2018-10-02 |
Family
ID=49882495
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014016024A MX359555B (es) | 2012-07-03 | 2013-07-03 | Anticuerpos para tau. |
MX2022000026A MX2022000026A (es) | 2012-07-03 | 2014-12-19 | Anticuerpos para tau. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022000026A MX2022000026A (es) | 2012-07-03 | 2014-12-19 | Anticuerpos para tau. |
Country Status (17)
Country | Link |
---|---|
US (2) | US9834596B2 (es) |
EP (2) | EP2870176A4 (es) |
JP (3) | JP6345655B2 (es) |
KR (3) | KR20200013072A (es) |
CN (2) | CN104781278B (es) |
AU (3) | AU2013286680B2 (es) |
BR (1) | BR112014033116B1 (es) |
CA (1) | CA2877397A1 (es) |
HK (1) | HK1209768A1 (es) |
IL (3) | IL236409B (es) |
IN (1) | IN2015KN00007A (es) |
MX (2) | MX359555B (es) |
MY (1) | MY171473A (es) |
NZ (2) | NZ739622A (es) |
RU (2) | RU2018132044A (es) |
SG (3) | SG10201913370PA (es) |
WO (1) | WO2014008404A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2018132044A (ru) | 2012-07-03 | 2018-10-19 | Вашингтон Юниверсити | Антитела против тау |
BR112015003326A2 (pt) * | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
PE20152004A1 (es) * | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン,インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
EP3486256A3 (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US10830775B2 (en) | 2014-09-30 | 2020-11-10 | Washington University | Tau kinetic measurements |
MA41451A (fr) * | 2015-02-04 | 2017-12-12 | Univ Washington | Constructions anti-tau |
TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對tau之抗體及其用途 |
TWI790642B (zh) | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
NZ738058A (en) * | 2015-07-06 | 2021-07-30 | UCB Biopharma SRL | Tau-binding antibodies |
CN107849105B (zh) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | Tau结合抗体 |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
EP3334761B1 (en) * | 2015-08-13 | 2023-07-19 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
CN109580954B (zh) * | 2015-09-16 | 2022-03-22 | 北京九强生物技术股份有限公司 | 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法 |
CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
KR102506091B1 (ko) | 2016-05-02 | 2023-03-07 | 프로테나 바이오사이언시즈 리미티드 | 타우 면역요법 |
TN2018000419A1 (en) | 2016-07-12 | 2020-06-15 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof. |
EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
MA46836A (fr) | 2016-11-15 | 2019-09-25 | H Lundbeck As | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
CN110248959B (zh) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
KR20230146126A (ko) | 2016-12-07 | 2023-10-18 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
CN106749658B (zh) * | 2016-12-15 | 2019-11-12 | 北京师范大学 | 抑制Tau蛋白聚集的抗体型分子伴侣 |
WO2018109058A1 (en) | 2016-12-16 | 2018-06-21 | H. Lundbeck A/S | Agents, uses and methods |
US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
CA3055957A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
TW202340244A (zh) * | 2017-10-16 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
JP2021519268A (ja) | 2018-03-23 | 2021-08-10 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 安定な水性抗タウ抗体製剤 |
US11629175B2 (en) | 2018-04-27 | 2023-04-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for preparing PHFS-like Tau aggregates |
CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
CN109613242A (zh) * | 2018-11-01 | 2019-04-12 | 深圳天辰医疗科技有限公司 | 一种肌酸激酶同工酶检测试剂盒及其制备方法 |
JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
AU2020241856A1 (en) | 2019-03-18 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation |
AU2020241858A1 (en) * | 2019-03-18 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation |
CN110055280A (zh) * | 2019-03-19 | 2019-07-26 | 深圳大学 | 一种稳定表达mCherry-tau的细胞系及其构建方法与应用 |
EP4001305A4 (en) * | 2019-07-15 | 2022-10-12 | Adel Inc. | ANTI-TAU ANTIBODIES AND ITS USE |
JP2022551478A (ja) | 2019-10-09 | 2022-12-09 | ブルーロック セラピューティクス エルピー | 持続的トランスジーン発現を伴う細胞 |
AU2020394842A1 (en) * | 2019-12-04 | 2022-06-30 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
US20220145363A1 (en) * | 2020-11-09 | 2022-05-12 | Meso Scale Technologies, Llc. | Methods and kits for detecting tau |
US20240101654A1 (en) | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
CA3214310A1 (en) | 2021-03-26 | 2022-09-29 | Rupesh Nanjunda | Anti-tau antibodies and uses thereof |
BR112023019205A2 (pt) | 2021-03-26 | 2023-10-24 | Janssen Biotech Inc | Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK546988A (da) | 1987-10-02 | 1989-04-03 | Du Pont | Immunobestemmelse og reagenssaet til anvendesle herved |
EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
US5733734A (en) | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
JP3909084B2 (ja) | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管結合タンパク質タウに対するモノクローナル抗体 |
CA2125298A1 (en) | 1991-12-06 | 1993-06-10 | Eva-Maria Mandelkow | Tools for the diagnosis and treatment of alzheimer's disease |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
JPH06239899A (ja) | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
JPH10506381A (ja) | 1994-07-29 | 1998-06-23 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 特定のサブクラスまたは形態のホスホリレーションされたtauのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用 |
WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
US6797478B1 (en) | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
RU2238947C2 (ru) * | 1998-07-14 | 2004-10-27 | Янссен Фармацевтика Н.В. | Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты) |
ES2229817T3 (es) | 1998-09-08 | 2005-04-16 | Innogenetics N.V. | Uso de la tau como un marcador para la deteccion temprana del daño del sistema nervioso central (cns). |
US6495376B1 (en) * | 1999-02-18 | 2002-12-17 | Beth Israel Deaconess Medical Center | Methods and compositions for regulating protein-protein interactions |
US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
EP3960855A1 (en) | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
LT1507556T (lt) | 2002-05-02 | 2016-10-10 | Wyeth Holdings Llc | Kalicheamicino darinio ir nešiklio konjugatai |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
US8288608B2 (en) | 2002-07-12 | 2012-10-16 | Axon Neuroscience Se | Transgenic animal expressing alzheimer's tau protein |
JP4393382B2 (ja) | 2002-08-14 | 2010-01-06 | 三菱化学株式会社 | 中枢性タウ蛋白質特異的抗体 |
FI20030652A0 (fi) | 2003-04-30 | 2003-04-30 | Susann Eriksson | Parannettu immunomääritys |
CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
KR20100087403A (ko) | 2005-02-19 | 2010-08-04 | 주식회사 피플바이오 | 멀티머-형성 폴리펩타이드의 모노머로부터 멀티머를 분별 검출하는 방법 |
WO2007019273A2 (en) | 2005-08-04 | 2007-02-15 | Albert Einstein College Of Medicine Of Yeshiva University | Phosphorylation of tau by abl |
ES2321996B1 (es) | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias. |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
ES2501565T3 (es) | 2008-04-24 | 2014-10-02 | Bristol-Myers Squibb Company | Uso de epotilona D en el tratamiento de enfermedades asociadas a Tau incluyendo enfermedad de Alzheimer |
CN101307108B (zh) | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
CA2937492C (en) * | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
US20110305706A1 (en) | 2009-02-23 | 2011-12-15 | Scott Thomas Brady | Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
US8409584B2 (en) | 2009-05-05 | 2013-04-02 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
CN102596236B (zh) * | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
JP6124591B2 (ja) | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
JP5909447B2 (ja) * | 2009-09-14 | 2016-04-26 | バンヤン・バイオマーカーズ・インコーポレーテッド | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
US8648044B2 (en) | 2009-09-24 | 2014-02-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction |
WO2011109112A2 (en) | 2010-03-05 | 2011-09-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of detecting tau protein and tau fragments in serum |
CN103502272B (zh) * | 2010-10-07 | 2016-06-15 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
AU2013205313B2 (en) | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
SI2627672T1 (sl) | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Človeška protitelesa anti-tau |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
US20120321594A1 (en) | 2011-05-06 | 2012-12-20 | New York University | Methods of controlling axon or dendrite development of neuronal cells |
JP6457263B2 (ja) | 2011-05-20 | 2019-01-23 | オリゴメリックス インコーポレイテッド | タウプロテアーゼ組成物および使用方法 |
GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
US9926353B2 (en) | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
AU2012311234B2 (en) | 2011-09-19 | 2017-09-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease |
EP3135689B1 (en) | 2011-10-07 | 2018-12-19 | AC Immune S.A. | Phosphospecific antibodies recognising tau |
WO2013063086A1 (en) | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
MY186066A (en) | 2011-12-20 | 2021-06-18 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
WO2013177104A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment for tauopathies |
US20150183854A1 (en) | 2012-05-31 | 2015-07-02 | Teijin Pharma Limited | Therapeutic agent or prophylactic agent for dementia |
RU2018132044A (ru) | 2012-07-03 | 2018-10-19 | Вашингтон Юниверсити | Антитела против тау |
BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
CA2885924C (en) | 2012-08-21 | 2022-12-13 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
CA2887933A1 (en) | 2012-10-12 | 2014-04-17 | Arizona Board Of Agents, On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
US9910048B2 (en) | 2012-12-03 | 2018-03-06 | Washington University | Method for detection of aggregates in biological samples |
US8921150B2 (en) | 2012-12-06 | 2014-12-30 | Taiwan Semiconductor Manufacturing Co., Ltd. | Process to achieve contact protrusion for single damascene via |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
WO2014096321A1 (en) | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
PT2935326T (pt) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
WO2014159244A2 (en) | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
US9598485B2 (en) | 2013-03-15 | 2017-03-21 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
-
2013
- 2013-07-03 RU RU2018132044A patent/RU2018132044A/ru unknown
- 2013-07-03 NZ NZ739622A patent/NZ739622A/en not_active IP Right Cessation
- 2013-07-03 EP EP13813988.6A patent/EP2870176A4/en not_active Withdrawn
- 2013-07-03 WO PCT/US2013/049333 patent/WO2014008404A1/en active Application Filing
- 2013-07-03 KR KR1020207002242A patent/KR20200013072A/ko not_active Application Discontinuation
- 2013-07-03 MY MYPI2014704038A patent/MY171473A/en unknown
- 2013-07-03 IN IN7KON2015 patent/IN2015KN00007A/en unknown
- 2013-07-03 US US14/412,309 patent/US9834596B2/en active Active
- 2013-07-03 EP EP20199802.8A patent/EP3838921A3/en not_active Withdrawn
- 2013-07-03 CN CN201380045706.3A patent/CN104781278B/zh active Active
- 2013-07-03 CA CA2877397A patent/CA2877397A1/en not_active Abandoned
- 2013-07-03 JP JP2015520685A patent/JP6345655B2/ja not_active Expired - Fee Related
- 2013-07-03 RU RU2015103228A patent/RU2668159C2/ru active
- 2013-07-03 MX MX2014016024A patent/MX359555B/es active IP Right Grant
- 2013-07-03 CN CN201810507442.3A patent/CN108623682A/zh active Pending
- 2013-07-03 SG SG10201913370PA patent/SG10201913370PA/en unknown
- 2013-07-03 SG SG10201708959WA patent/SG10201708959WA/en unknown
- 2013-07-03 NZ NZ703423A patent/NZ703423A/en not_active IP Right Cessation
- 2013-07-03 BR BR112014033116-2A patent/BR112014033116B1/pt active IP Right Grant
- 2013-07-03 KR KR1020207033554A patent/KR102494798B1/ko active IP Right Grant
- 2013-07-03 SG SG11201408626YA patent/SG11201408626YA/en unknown
- 2013-07-03 AU AU2013286680A patent/AU2013286680B2/en active Active
- 2013-07-03 KR KR20157002867A patent/KR20150036346A/ko active IP Right Grant
-
2014
- 2014-12-19 MX MX2022000026A patent/MX2022000026A/es unknown
- 2014-12-23 IL IL236409A patent/IL236409B/en active IP Right Grant
-
2015
- 2015-10-28 HK HK15110657.6A patent/HK1209768A1/xx unknown
-
2017
- 2017-06-02 US US15/612,695 patent/US20180037641A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098889A patent/JP2018184398A/ja active Pending
- 2018-09-17 AU AU2018229564A patent/AU2018229564A1/en not_active Abandoned
-
2020
- 2020-04-09 JP JP2020070416A patent/JP2020125310A/ja active Pending
- 2020-08-28 AU AU2020223765A patent/AU2020223765A1/en not_active Abandoned
- 2020-09-29 IL IL277643A patent/IL277643A/en unknown
-
2021
- 2021-12-21 IL IL289241A patent/IL289241A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000026A (es) | Anticuerpos para tau. | |
PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
IL245237A0 (en) | New anti-claudin antibodies and methods of use | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
MX2015013901A (es) | Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos. | |
IN2015DN00127A (es) | ||
EP2970508A4 (en) | GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
IL245946A0 (en) | Anti-dpep3 antibodies and methods of use | |
IN2014DN08721A (es) | ||
MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
IN2013MU00848A (es) | ||
IN2014DN09450A (es) | ||
MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
MX361773B (es) | Agentes de ligación a tlr3. | |
MX2015010789A (es) | Anticuerpos anti-pcsm. | |
NZ743971A (en) | Antibodies to tau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |